scispace - formally typeset
G

Giles A. Rae

Researcher at Universidade Federal de Santa Catarina

Publications -  114
Citations -  3096

Giles A. Rae is an academic researcher from Universidade Federal de Santa Catarina. The author has contributed to research in topics: Endothelin receptor & Endothelins. The author has an hindex of 33, co-authored 113 publications receiving 2951 citations.

Papers
More filters
Journal ArticleDOI

Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice

TL;DR: The results suggest that centrally administered NK1 and NK2 receptor agonists and antagonists can modulate anxiety, as evaluated in the elevated plus-maze test in mice.
Journal ArticleDOI

Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test.

TL;DR: Results indicate that blockade of the N/OFQ‐NOP receptor signalling in the brain produces antidepressant‐like effects in the mouse FST, and support the NOP receptor as a candidate target for the development of innovative antidepressant drugs.
Journal ArticleDOI

Endothelin‐1‐induced ETA receptor‐mediated nociception, hyperalgesia and oedema in the mouse hind‐paw: modulation by simultaneous ETB receptor activation

TL;DR: Endothelin‐1 triggers ETA receptor‐mediated nociception, hyperalgesia and oedema in the mouse hind‐paw, and simultaneous activation of ETB receptors by endothelins‐1 or selective agonists can limit thehyperalgesic, but not the nocICEptive or oedematogenic, effects of the peptide.
Journal ArticleDOI

Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: new evidence from rats and mice

TL;DR: UFP-101 exhibits pronounced antidepressant-like effects in different species and animal models, possibly by preventing the inhibitory effects of endogenous N/OFQ on brain monoaminergic (in particular serotonergic) neurotransmission.
Journal ArticleDOI

Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection

TL;DR: The dual anti-inflammatory and analgesic properties of LXA4, allied to its endogenous nature and safety profile, may render this lipid mediator as new therapeutic approach for treating various neuroinflammatory disorders and chronic pain with only limited side effects.